Taysha Gene Therapies, Inc. - 8-K Filing

Taysha Gene Therapies reports Q3 2026 net loss of $39.1 million and announces successful BLA-enabling PPQ manufacturing campaign for TSHA-102. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 12:38 UTC

Tickers: $TSHA

Read the full article at SEC EDGAR

Part of the story Taysha Gene Therapies, Inc. - 10-Q Filing (2 articles)

More Regulatory news

LiveRamp Holdings, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 16:52 UTC
Presurance Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 16:43 UTC
EXPEDITORS INTERNATIONAL OF WASHINGTON INC - 8-K Filing SEC EDGAR · November 12, 2026, 16:42 UTC
AUDIOEYE INC - 10-Q Filing SEC EDGAR · October 26, 2026, 21:11 UTC
ROCKWELL AUTOMATION, INC - 10-K Filing SEC EDGAR · November 12, 2026, 16:35 UTC
United KSK Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 16:29 UTC
AMERICAN SHARED HOSPITAL SERVICES - 8-K Filing SEC EDGAR · November 12, 2026, 16:27 UTC
VIVIC CORP. - 10-K Filing SEC EDGAR · November 12, 2026, 16:26 UTC
WOLVERINE WORLD WIDE INC /DE/ - 10-Q Filing SEC EDGAR · November 12, 2026, 16:24 UTC
BlueOne Technologies, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 16:20 UTC